Literature DB >> 32946430

Stem cell therapy for muscular dystrophies.

Stefano Biressi1,2, Antonio Filareto3, Thomas A Rando4,5,6.   

Abstract

Muscular dystrophies are a heterogeneous group of genetic diseases, characterized by progressive degeneration of skeletal and cardiac muscle. Despite the intense investigation of different therapeutic options, a definitive treatment has not been developed for this debilitating class of pathologies. Cell-based therapies in muscular dystrophies have been pursued experimentally for the last three decades. Several cell types with different characteristics and tissues of origin, including myogenic stem and progenitor cells, stromal cells, and pluripotent stem cells, have been investigated over the years and have recently entered in the clinical arena with mixed results. In this Review, we do a roundup of the past attempts and describe the updated status of cell-based therapies aimed at counteracting the skeletal and cardiac myopathy present in dystrophic patients. We present current challenges, summarize recent progress, and make recommendations for future research and clinical trials.

Entities:  

Year:  2020        PMID: 32946430      PMCID: PMC7598050          DOI: 10.1172/JCI142031

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  184 in total

1.  Aldehyde dehydrogenase activity identifies a population of human skeletal muscle cells with high myogenic capacities.

Authors:  Karine Vauchez; Jean-Pierre Marolleau; Michel Schmid; Patricia Khattar; Alain Chapel; Cyril Catelain; Séverine Lecourt; Jérôme Larghéro; Marc Fiszman; Jean-Thomas Vilquin
Journal:  Mol Ther       Date:  2009-09-08       Impact factor: 11.454

2.  ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs.

Authors:  Michael R Hicks; Julia Hiserodt; Katrina Paras; Wakana Fujiwara; Ascia Eskin; Majib Jan; Haibin Xi; Courtney S Young; Denis Evseenko; Stanley F Nelson; Melissa J Spencer; Ben Van Handel; April D Pyle
Journal:  Nat Cell Biol       Date:  2017-12-18       Impact factor: 28.824

3.  Duchenne muscular dystrophy: plasma membrane loss initiates muscle cell necrosis unless it is repaired.

Authors:  S Carpenter; G Karpati
Journal:  Brain       Date:  1979-03       Impact factor: 13.501

4.  Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosuppression are able to reach the host muscle and express human dystrophin.

Authors:  N M Vieira; M Valadares; E Zucconi; M Secco; C R Bueno; V Brandalise; A Assoni; J Gomes; V Landini; T Andrade; H V A Caetano; M Vainzof; M Zatz
Journal:  Cell Transplant       Date:  2012       Impact factor: 4.064

5.  Isolation and characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies.

Authors:  Roberta Morosetti; Massimiliano Mirabella; Carla Gliubizzi; Aldobrando Broccolini; Cristina Sancricca; Mario Pescatori; Teresa Gidaro; Giorgio Tasca; Roberto Frusciante; Pietro Attilio Tonali; Giulio Cossu; Enzo Ricci
Journal:  Stem Cells       Date:  2007-08-30       Impact factor: 6.277

6.  Engraftment of ES-Derived Myogenic Progenitors in a Severe Mouse Model of Muscular Dystrophy.

Authors:  Antonio Filareto; Radbod Darabi; Rita C R Perlingeiro
Journal:  J Stem Cell Res Ther       Date:  2012-01-06

7.  Interleukin-4 improves the migration of human myogenic precursor cells in vitro and in vivo.

Authors:  J F Lafreniere; P Mills; M Bouchentouf; J P Tremblay
Journal:  Exp Cell Res       Date:  2006-02-07       Impact factor: 3.905

8.  Myoblast transfer in Duchenne muscular dystrophy.

Authors:  G Karpati; D Ajdukovic; D Arnold; R B Gledhill; R Guttmann; P Holland; P A Koch; E Shoubridge; D Spence; M Vanasse
Journal:  Ann Neurol       Date:  1993-07       Impact factor: 10.422

9.  Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts.

Authors:  Maurilio Sampaolesi; Yvan Torrente; Anna Innocenzi; Rossana Tonlorenzi; Giuseppe D'Antona; M Antonietta Pellegrino; Rita Barresi; Nereo Bresolin; M Gabriella Cusella De Angelis; Kevin P Campbell; Roberto Bottinelli; Giulio Cossu
Journal:  Science       Date:  2003-07-10       Impact factor: 47.728

10.  Ex Vivo Expansion and In Vivo Self-Renewal of Human Muscle Stem Cells.

Authors:  Gregory W Charville; Tom H Cheung; Bryan Yoo; Pauline J Santos; Gordon K Lee; Joseph B Shrager; Thomas A Rando
Journal:  Stem Cell Reports       Date:  2015-09-03       Impact factor: 7.765

View more
  21 in total

1.  Plasmonic fusion between fibroblasts and skeletal muscle cells for skeletal muscle regeneration.

Authors:  Limor Minai; Dvir Yelin
Journal:  Biomed Opt Express       Date:  2022-01-06       Impact factor: 3.732

Review 2.  Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle.

Authors:  Olivier Boyer; Gillian Butler-Browne; Hector Chinoy; Giulio Cossu; Francesco Galli; James B Lilleker; Alessandro Magli; Vincent Mouly; Rita C R Perlingeiro; Stefano C Previtali; Maurilio Sampaolesi; Hubert Smeets; Verena Schoewel-Wolf; Simone Spuler; Yvan Torrente; Florence Van Tienen
Journal:  Front Genet       Date:  2021-08-02       Impact factor: 4.599

Review 3.  Ageing and rejuvenation of tissue stem cells and their niches.

Authors:  Anne Brunet; Margaret A Goodell; Thomas A Rando
Journal:  Nat Rev Mol Cell Biol       Date:  2022-07-20       Impact factor: 113.915

Review 4.  Stem Cell-derived Extracellular Vesicles: A Promising Nano Delivery Platform to the Brain?

Authors:  Yuying Guo; Dongsheng Hu; Lu Lian; Linna Zhao; Mingli Li; Huijing Bao; Shixin Xu
Journal:  Stem Cell Rev Rep       Date:  2022-09-29       Impact factor: 6.692

5.  Netrin-1 promotes the vasculogenic capacity of human adipose-derived stem cells.

Authors:  Ming-Lian Luo; Jian-Wen Zhu; Xue-Mei Gao
Journal:  Cell Tissue Bank       Date:  2022-10-12       Impact factor: 1.752

6.  Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.

Authors:  Maria Siemionow; Paulina Langa; Sonia Brodowska; Katarzyna Kozlowska; Kristina Zalants; Katarzyna Budzynska; Ahlke Heydemann
Journal:  Stem Cell Rev Rep       Date:  2022-05-19       Impact factor: 6.692

7.  Evidence of Stem Cell Efficacy on Developmental and Functional Alterations in Craniofacial Diseases.

Authors:  Marco Tatullo; Gianrico Spagnuolo
Journal:  J Clin Med       Date:  2021-01-15       Impact factor: 4.241

8.  Base editing repairs an SGCA mutation in human primary muscle stem cells.

Authors:  Helena Escobar; Anne Krause; Sandra Keiper; Janine Kieshauer; Stefanie Müthel; Manuel García de Paredes; Eric Metzler; Ralf Kühn; Florian Heyd; Simone Spuler
Journal:  JCI Insight       Date:  2021-05-24

9.  MRTF-A regulates myoblast commitment to differentiation by targeting PAX7 during muscle regeneration.

Authors:  Ruhui Song; Shengnan Zhao; Yue Xu; Jian Hu; Shuangao Ke; Fan Li; Gaohui Tian; Xiao Zheng; Jiajun Li; Lixing Gu; Yao Xu
Journal:  J Cell Mol Med       Date:  2021-08-04       Impact factor: 5.310

10.  Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.

Authors:  Maria Siemionow; Paulina Langa; Michal Harasymczuk; Joanna Cwykiel; Magdalena Sielewicz; Jaroslaw Smieszek; Ahlke Heydemann
Journal:  Stem Cells Transl Med       Date:  2021-07-22       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.